Familial Mediterranean fever-associated infertility and underlying factors
- 50 Downloads
Familial Mediterranean fever (FMF) is characterized by recurrent attacks of fever, serositis, and arthritis, but some patients may experience long-term complications of disease such as infertility/subfertility. The published data about FMF-associated infertility is still limited. The aim of this study is to investigate the frequency and to determine potential factors for FMF-associated infertility/subfertility.
We enrolled 971 adult patients with FMF. We defined infertility as the failure to conceive after 12 months of regular, unprotected intercourse. All patients fulfilled Tel Hashomer criteria. Demographic data, FMF disease characteristics and genotype data (if available), disease complications, laboratory parameters, and treatment features were recorded.
There were 582 subjects eligible for the present study (mean age 41.05 ± 10.6 years, 65.8% female). MEFV mutations were available in 482 subjects, and 74.9% of subjects were harboring M694 V mutation (25.1% homozygous for M694 V). Infertility was present in 64 patients (14.6% of females and 4% of males). Multivariate analysis showed female sex [odds ratio (OR), 4.47; 95% confidence interval (CI95%) 1.75–11.42; p = 0.002], FMF disease onset < 20 years [OR, 2.99; (CI95% 1.04–8.61);p = 0.04], disease severity (ISSF) [OR, 4.81; (CI95% 2.28–10.17); p < 0.001], and colchicine nonresponse [OR, 2.80; (CI95% 1.17–6.74) p = 0.021] were the independent predictors of infertility. We also observed reversal of infertility in five patients who were treated with IL-1 β antagonists.
• The prevalence of infertility increased in female patients with FMF.
• Female sex, FMF disease onset < 20 years, disease severity, and colchicine nonresponse were risk factors for FMF-associated infertility.
• With effective treatment of FMF, reversal of infertility was observed in five patients.
KeywordsColchicine resistance Familial Mediterranean fever Infertility Inflammation Interleukin-1 β antagonists
This work was supported by grants from Hacettepe Rheumatology Association. Grant No. HRD2018-001.
Compliance with ethical standards
- 1.Gafni J, Ravid M, Sohar E (1968) The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med Sci 4(5):995–999Google Scholar
- 12.Ehrenfeld EN, Polishuk WZ (1970) Gynecological aspects of recurrent polyserositis (familial Mediterrranean fever, periodic disease). Isr J Med Sci 6(1):9–13Google Scholar
- 14.Mamou H (1970) Periodic disease and endocrine disorders. Sem Hop 46(29):2024–2029Google Scholar
- 15.Ben-Chetrit A, Ben-Chetrit E, Nitzan R, Ron M (1993) Colchicine inhibits spermatozoal motility in vitro. Int J Fertil Menopausal Stud 38(5):301–304Google Scholar
- 17.Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885. https://doi.org/10.1002/1529-0131(199710)40:10<1879::AID-ART23>3.0.CO;2-M CrossRefGoogle Scholar
- 19.Demirkaya E, Acikel C, Hashkes P, Gattorno M, Gul A, Ozdogan H, Turker T, Karadag O, Livneh A, Ben-Chetrit E, Ozen S, FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) (2016) Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75(6):1051–1056. https://doi.org/10.1136/annrheumdis-2015-208671 CrossRefGoogle Scholar
- 20.Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U et al (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 34(7):1540–1544Google Scholar
- 21.Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188. https://doi.org/10.1016/j.semarthrit.2007.03.005 CrossRefGoogle Scholar
- 24.Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690 CrossRefGoogle Scholar
- 25.Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S et al (2018) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 1–4. https://doi.org/10.1080/14397595.2018.1457469